JPMorgan initiates Anthem Biosciences stock with Neutral rating

JPMorgan initiated coverage on Anthem Biosciences (ANTHEM:IN) with a Neutral rating and an INR820.00 price target. While the innovation-led CRDMO is projected for a 26% EPS CAGR (FY25-28E) and has significantly outperformed the NSE Pharma Index since its July 2025 listing, JPM cited valuation concerns, noting the stock trades at a substantial premium (e.g., 63x FY27E P/E) to its sector average, implying capped upside.

Analysis

JPMorgan has initiated coverage on Anthem Biosciences with a Neutral rating and an INR820.00 price target, presenting a balanced view of the company's prospects. The firm highlights Anthem's strong fundamental profile as an innovation-led CRDMO, forecasting a robust 26% earnings per share (EPS) compound annual growth rate (CAGR) between FY25 and FY28. This positive outlook is supported by the company's expansion into high-growth segments like ADCs and peptides, a healthy pipeline, and favorable industry tailwinds. The stock's performance has been exceptional, surging 48% since its July 2025 listing, in stark contrast to the NSE Pharma Index's 1.0% decline over the same period. However, the Neutral rating is driven by significant valuation concerns. Anthem currently trades at approximately 63 times its FY27 estimated earnings and 52 times its FY28 earnings, representing a 45% premium to its sector average and an 18% premium to its peer, DIVI. This suggests that the market has already priced in the strong growth expectations, leaving limited near-term upside from current levels.

Key Decisions for Investors

• Given the stock's 48% outperformance since its IPO and the 'Neutral' rating based on a high valuation, existing investors may consider trimming their positions to realize profits as further upside appears capped.
• Potential investors should be cautious of the demanding valuation, which stands at a 45% premium to the sector, and might await a more favorable entry point despite the company's strong long-term growth profile.
• Monitor future earnings releases closely to validate if the company can sustain the high growth required to justify its premium valuation, as any deviation from the forecasted 26% EPS CAGR could trigger a de-rating of the stock.